Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 11 to 14 amino acid residues in defined sequence
Reexamination Certificate
2007-01-23
2007-01-23
Helms, Larry R. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
11 to 14 amino acid residues in defined sequence
C424S185100
Reexamination Certificate
active
10257603
ABSTRACT:
The present invention provides a method for producing a vaccine against cancerous disease, and the vaccine itself. This method involves first using one or more antibodies that are specifically effective against one or more antigens specially expressed by the tumor cells to select one or more mimotopes of said antigens from a phage peptide library. To obtain the vaccine, said mimotopes are conjugated to a macromolecular carrier singly or multiply in the form of their mono-, di-, tri- or oligomers. When administered, the inventively produced vaccine leads to a humoral immune response and thus to the formation of an active immunity as a consequence of vaccination.
REFERENCES:
patent: 5772997 (1998-06-01), Hudziak et al.
patent: 5801005 (1998-09-01), Cheever et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 6610297 (2003-08-01), Kricek et al.
patent: 117165 (1993-05-01), None
patent: WO 96/18409 (1996-06-01), None
patent: WO 99/33969 (1999-08-01), None
patent: WO 99/57981 (1999-11-01), None
patent: WO 01/08636 (2001-02-01), None
Zhu et al. PMSA mimotype isolated from phage displayed peptide library can induce PMSA specific immune response. Cell Research 9:271-280 (1999).
Perosa et al. Ann. N.Y. Acad. Sci. 1051: 672-683, 2005.
DeGruijl et al. Nature Medicine 5(10): 1124-1125, Oct. 1999.
Mellman I. The Scientist 20(1): 47, 2006.
Bodey B. et al. Anticancer Research 20: 2665-2676, 2000.
Baselga et al. (1988) “Recombinant Humanized Anti-HER2 Antibody (Herceptin) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2
eu Overexpressing Human Breast Cancer Xenografts”,Cancer Research58: 2825-2831.
Baselga. et al. (2000) “Phase I Studies of Anti-Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin”,Journal of Clinical Oncology,vol. 18, No. 4, pp. 904-914.
Behr et al. (1999) Low-versusHigh-Dose Radioimmunotherapy with Humanized Anti-CD22 or Chimeric Anti-CD20 Antibodies in a Broad Spectrum of B Cell-associated Malignancies,Clinical Cancer Researchvol. 5. 3304s-3314s.
Braun et al. (1999) Monoclonal Antibody Therapy with Edrecolomab in Breast Cancer Patients: Monitoring of Elimination of Disseminated Cytokeratin-positive Tumor Cellsin Bone Marrow Clinical Cancer Researchvol. 5, 3999-4004.
Cha et al. (1996) “Random phage mimotopes recognized by monoclonal antibodies against the pyruvate dehydrogenase complex-E2 (PDC-E2)”,Proc. Natl. Acad. Sci. USA,vol. 93, pp. 10949-10954 Immunology.
D'Mello et al. (1997) “Definition of the Primary Structure of Hepatitis B Virus (HBV) pre-S Hepatocyte Binding Domain Using Random Peptide Libraries”Virologyvol. 237, pp. 319-326.
Huang et al. (1999) “Epidermal Growth Factor Receptor Blockade with C225 Modulates Proliferation, Apoptosis, and Radiosensitivity in Squamous Cell Carcinomas of the Head and Neck”Cancer Researchvol. 59, pp. 1935-1940.
Martin. et al. (1999) “Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: a potential immunotherapeutic target?”J. Clin. Pathol,vol. 52, pp. 701-704.
McCormick et al. (1999) “Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv Epitopes in tobacco plants”Proc. Natl.Acad. Sci USA vol. 96, pp. 703-708 Medical Sciences.
Milpied. et al. (2000) “Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients” Annals of Oncology II Suppl.S113-S116 Kluwer Academic Publishers.
Orlandi et al. (1994) “Antigenic and Immunogenic mimicry of the HER2
eu oncoprotein by phage-displayed peptides”Eur. J. Immunol.vol. 24, pp. 2868-2873.
Poczatek et al (1999) “Ep-Cam Levels in Prostatic Adenocarcinoma and Prostatic Intraepithelial Neoplasia”The Journal of Urology,vol. 162, pp. 1462-1466.
Punt (1998) “New Drugs in the Treatment of Colorectal Carcinoma”CANCER,vol. 83, No. 4 pp. 679-689.
Riethmuller et al. (1994) “Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma”The Lancet,vol. 343, pp. 1177-1183.
Samonigg et al. (1999) “A Double-Blind Randomized-Phase II Trial Comparing Immunization with Antiidiotype Goat Antibody Vaccine SVC 106 Versus Upspecific Goat Antibodies in Patients with Metastatic Colorectal Cancer”Journal of Immunotherapy,vol. 22(6): pp. 481-488.
Stoute et al. (1995) “Induction of Humoral Immune Response againstPlasmodium falciparumSporozoites by Immunication with a Synthetic Peptide Mimotope Whose Sequence Was Derived from Screening a Filamentous Phage Epitope Library”Infection and Immunity,vol. 63, No. 3 pp. 934-939.
Treon et al. (2000) “Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens”Annals of OncologyII Supp S107-S111.
Turpen et al. (1995) “Malarial Epitopes Expressed on the Surface of Recombinant Tobacco Mosaic Virus”BiolTechnologyvol. 13, pp. 53-57.
Zwick, et al. (1998) “Phage-displayed peptide libraries”Current Opinion in Biotechnology,vol. 9 pp. 427-436.
Mittelman, Abraham et al., “Human high molecular weight melanoma-associated antigen (HMV-MAA) mimicry by mouse anti-idiotype monoclonal antibody MK2-23: Induction of humoral anti-HMV-MAA Immunity and prolongation of survival in patients with stage IV melanoma,” Proc. Natl. Acad. Sci. USA, vol. 89, pp. 446-470. Jan. 1992.
Mittelman, A. et al., “Active Specific Immunotherapy in Patients with Melanoma. A Clinical Trial with Mouse Antiidiotypic Monoclonal Antibodies Elicited with Syngeneic Anti-High-Molecular-Weight-Melanoma-Associated Antigen Monoclonal Antibodies,” J. Clin. Invest. Dec. 1990, 86, 2136-2144.
Geiser, Martin et al., “Identification of the Human Melanoma-associated Chondroitin Sulfate Proteoglycan Antigen Epitope Recognized by the Antitumor Monoclonal Antibody 763.74 from a Peptide Phage Library,” Cancer Research 59, 905-910, Feb. 15, 1999.
Mittelman, Abraham et al., “Human High Molecular Weight-Melanoma Associated Antigen Mimicry by Mouse Anti-Idiotypic Monoclonal Antibody MK2-23: Modulation of the Immunogenicity in Patients with Malignant Melanoma,” Clinical Cancer Research vol. 1, 705-173, Jul. 1995.
Ziai, M. Reza et al., “Analysis with Monoclonal Antibodies of the Molecular and Cellular Heterogeneity of Human High Molecular Weight Melanoma Associated Antigen,” Cancer Research 47, 2474-2480, May 1, 1987.
Price, Michael et al., “Enhancement of Cell-mediated Immunity in Melanoma Patients Immunized with Murine Anti-Idiotypic Monoclonal Antibodies (MELIMMUNE) That Mimic the High Molecular Weight Proteoglycan Antigen,” Clinical Cancer Research vol. 4, 2363-2370 Oct. 1998.
Ferrone, S. et al., “Active Specific Immunotherapy of Malignant Melanoma and Peptide Mimics of the Human High-Molecular-Weight Melanoma-Associated Antigen,” Recent Results Cancer Res., 2001, 158, 231-5).
Wison, Barry S. et al., Distribution and Molecular Characterization of a Cell-Surface and a Cytoplasmic Antigen Detectable in Human Melanoma Cells with Monoclonal Antibodies, Int. J. Cancer: 28, 293-300 (1981).
Leitner, Agnes et al., “A mimotope defines by phage display inhibits IgE binding to the plant panallergen profilin,” Eur. J. Immunol. 1998, 28:2921-2927.
Breiteneder Heimo
Jensen-Jarolim Erika
Penamberger Hubert
Scheiner Otto
Zielinski Christoph
Helms Larry R.
Humphrey David
Milbank Tweed Hadley & McCloy LLP
LandOfFree
Vaccine against cancerous diseases which is based on... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine against cancerous diseases which is based on..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine against cancerous diseases which is based on... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3769435